Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo by Meng, Jieru et al.
Combination Treatment with MEK and AKT Inhibitors Is
More Effective than Each Drug Alone in Human Non-




1, B. Nebiyou Bekele




3, Roy S. Herbst
4, Vassiliki Papadimitrakopoulou





1Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas,
United States of America, 2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 3Department of
Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 4Department of Thoracic/Head & Neck
Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 5Hamon Center for Therapeutic Oncology Research,
and Simmons Cancer Center, The University of Texas Southwestern Medical Center at Dallas, Texas, United States of America
Abstract
AZD6244 and MK2206 are targeted small-molecule drugs that inhibit MEK and AKT respectively. The efficacy of this
combination in lung cancer is unknown. Our previous work showed the importance of activated AKT in mediating
resistance of non-small cell lung cancer (NSCLC) to AZD6244. Thus we hypothesized that dual inhibition of both
downstream MEK and AKT pathways would induce synergistic antitumor activity. In this study, we evaluated the efficacy of
AZD6244 and MK2206 individually on a large panel of lung cancer cell lines. Then, we treated 28 human lung cancer cell
lines with a combination of AZD6244 and MK2206 at clinically applicable drug molar ratios. The AZD6244-MK2206
combination therapy resulted in a synergistic effect on inhibition of lung cancer cell growth compared to the results of
single drug treatment alone. MK2206 enhanced AZD6244-induced Bim overexpression and apoptosis in A549 and H157
cells. When we tested the combination of AZD6244 and MK2206 at ratios of 8:1, 4:1, 2:1, and 1:8, we found that the
synergistic effect of the combination therapy was ratio-dependent. At ratios of 8:1, 4:1, and 2:1, the drug combination
consistently demonstrated synergy, whereas decreasing the ratio to 1:8 resulted in a loss of synergy and produced an
additive or antagonistic effect in most cell lines. Furthermore, the AZD6244-MK2206 combination therapy showed synergy
in the suppression of A549 and H157 xenograft tumor growth and increased mean animal survival time. The AZD6244-
MK2206 combination therapy resulted in effective inhibition of both p-ERK and p-AKT expression in tumor tissue. In
addition, a significant increase of apoptosis was detected in tumor tissue from mice treated with AZD6244-MK2206
compared with that from the single agent treated mice. Our study suggests that the combination of AZD6244 and MK2206
has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing
highly aggressive human lung tumors.
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Introduction
The phosphatidylinositol 3-kinase (PI3K)/Akt and RAS/RAF/
mitogen-activated protein kinase (MEK)/extracellular signal-
regulated kinase (ERK) pathways, mediate proliferation and
survival in human lung cancer cells and share several downstream
molecules, such as FOXO3a [1], caspase-9 [2], and Bad [3].
Currently, a wide range of small-molecule tyrosine kinase
inhibitors that target signaling pathways have been developed, and
two of these agents are currently being evaluated in clinical trials.
AZD6244 is an allosteric inhibitor of the MEK1/2 kinases that
does not compete with adenosine triphosphate (ATP) binding
activity [4]. This compound binds to MEK1/2 and induces several
conformational changes in the unphosphorylated MEK1/2
enzymes, inhibiting their catalytic activity, which results in an
inhibition of ERK activation and a blockade of the signal
transduction pathways. MK2206 is a highly selective non-ATP
competitive allosteric inhibitor of AKT with IC50 in the nM range
and has broad preclinical antitumor activity. It is also in early
phase clinical trials and is being evaluated in the treatment of
patients with lung cancer. However, the potential efficacy of a
combination of AZD6244 and MK2206 in the treatment of lung
cancer is unknown. In this study, we investigated the effect of the
combination of AZD6244 and MK2206 in killing human lung
cancer cell lines and found that this combination was highly
synergistic in vitro and very effective in the treatment of lung cancer
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14124xenografts. We also explored the mechanism of synergism for
these two compounds. Our preclinical findings support clinical




AZD6244 and MK2206, synthesized in Dr. William G.
Bornmann’s laboratory at The University of Texas MD Anderson
Cancer Center, were dissolved to concentrations of 25 mM and
20 mM, respectively, in dimethyl sulfoxide and stored at 280uC.
Antibodies against total and phosphorylated ERK and AKT were
purchased from Cell Signaling Technology (Danvers, MA).
Antibodies against Bim were obtained from Calbiochem (San
Diego, CA). Protease inhibitor cocktail, b-actin antibody, and
sulforhodamine B were obtained from Sigma Chemical Corpora-
tion (St. Louis, MO). Protein assay materials were purchased from
Bio-Rad Laboratories (Hercules, CA). DeadEnd
TM Flurometic
TUNEL System was purchased from Promega (Madison, WI).
Cell culture
All the human lung cancer cell lines were provided by either Dr.
John V. Heymach at MD Anderson Cancer Center or Drs. Adi
Gazdar and John D. Minna at The University of Texas
Southwestern Medical Center at Dallas. The cell lines were
maintained in RPMI 1640 or high-glucose Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10% fetal bovine
serum, 100 mg/mL ampicillin, and 0.1 mg/mL streptomycin; the
cells were cultured at 37uC in a humidified atmosphere containing
5% CO2 and 95% air.
Cell viability assay
The inhibitory effects of AZD6244, MK2206, and the
combination of AZD6244 and MK2206 on cell growth were
determined by using the sulforhodamine B assay, as described
previously [5]. Each experiment was performed in quadruplicate
and repeated at least three times. The relative cell viability (%) was
calculated using the equation ODT/ODC6100% (where ODT
represents the absorbance of the treatment group and ODC
represents the absorbance of the control group). The median
inhibitory concentration (IC50) values were determined using
CurveExpert 1.3 software and plotted in dose-response curves.
Western blot analysis
Whole-cell lysates were prepared by washing the cells with
phosphate buffered saline (PBS) and subjecting them to lysis with
Laemmli sample buffer supplemented with the protease inhibitor
cocktail. After the lysates were sonicated for 15 s, the protein
concentrations were quantified using the Bio-Rad protein assay
kit. Equivalent amounts of each protein were loaded, separated by
10% or 12% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis, and then transferred to Polyvinylidene Fluoride (PVDF)
membranes at 80 V for 2 h. The membranes were blocked for 1 h
with 5% nonfat dried milk in PBS buffer containing 0.1% Tween-
20 (PBST) and probed with diluted primary antibody at 4uC
overnight. The membranes were then washed three times in the
PBST buffer and probed with infrared dye-labeled secondary
antibodies; the immunoreactive bands were visualized with the
Odyssey Imager (Li-COR Biosciences, Lincoln, NE).
Cell cycle and apoptosis assays
The cells were harvested by trypsinization, washed twice in cold
PBS, fixed with ice cold 70% methanol, and incubated at 4uC
overnight. Cells were then washed with PBS and incubated with
25 mg/mL propidium iodide containing 30 mg/mL ribonuclease
for 30 min at room temperature. Cells were analyzed on an
EPICS Profile II flow cytometer (Coulter Corp., Hialeah, FL)
using the Multicycle AV software (Phoenix Flow Systems, San
Diego, CA). Experiments were repeated at least three times.
Animal studies
All Animal experiments were carried out after approval by the
MD Anderson institutional review board (11-03-09932) and were
performed in accordance with the Guidelines for the Care and Use
of Laboratory Animals published by the National Institutes of
Health.
Female BALB/c nude mice were purchased from Charles River
Laboratories (Wilmington, MA). The mice were housed in laminar
flow cabinets under specific pathogen-free conditions and were
used when they were 6- to 8-weeks old. A total of 3610
6 H157 or
A549 cells were inoculated subcutaneously into the right dorsal
flanks of the nude mice. When the tumors reached an average
volume of about 0.1 cm
3, the mice were randomly divided into
control and treatment groups (n=5 animals per group). For the
H157-bearing mice, the treatment groups were administered
20 mg/kg AZD6244, 10 mg/kg MK2206, or AZD6244-MK2206
combination at 20mg/kg–10mg/kg, all of which had been
solubilized in a medium containing 0.5% hydroxypropyl methyl-
cellulose and 0.1% polysorbate buffer. In the A549-bearing mice,
the treatment groups were administered 24 mg/kg AZD6244,
6 mg/kg MK2206, or AZD6244-MK2206 combination at 24mg/
kg–6mg/kg, all of which had been solubilized in a medium
containing 0.5% hydroxypropyl methylcellulose and 0.1% poly-
sorbate buffer. All drugs were dissolved in 100ml vehicle buffer for
each mouse. All drugs administered twice daily by oral gavage.
The control group received the vehicle buffer alone. The
treatment duration was 20 d. Tumor size, measured by calipers,
was recorded every 5 d. The tumor volume was calculated, taking
length to be the longest diameter across the tumor and width to be
the corresponding perpendicular diameter, using the following
formula: length6width
260.52. The tumor growth inhibition rate
was calculated as 100%6(tumor sizetreated/tumor sizecontrol)o n
each measurement day. Tumor-bearing mice continued treatment
as indicated above after 20 d. Mice were allowed to live up to their
natural death or were sacrificed when their tumor volume was
larger than 2000 mm
3. Kaplan-Meier survival curves were plotted
and statistically analyzed. Animal body weight was measured and
recorded every 5 d during the treatment.
For the pharmacodynamic study, tumors were established as
described above and were allowed to grow to a size of 0.5–0.8cm
3
before treatment started. Mice bearing s.c. A549 tumors were then
daily administered vehicle, AZD6244, MK2206 or AZD6244-
MK2206 at the same concentrations mentioned above (n=5
animals per group) for 3 days. Four hours after the last dose,
animals were euthanized and tumors were resected, fixed with 4%
paraformaldehyde and paraffin-embedded for immunohistochem-
istry staining and TUNEL assay.
Immunohistochemistry
The sections were deparaffinized in xylene and serial ethanol
dilutions. The antigens were retrieved and endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide for 10 min.
The sections were then treated with 10% normal goat or horse
serum for 30 min. After overnight incubation with primary
antibodies, including p-AKT (dilution 1:100) and p-ERK (dilution
1:100), the sections were probed with biotinylated secondary
antibodies and then incubated with streptavidin-biotin-complex
Combine MEK and AKT Inhibitors
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solution of 3,3-diaminobenzidine tetrahydrochloride (DAB; Lab
Vision, Fremont, CA), counterstained with Mayer’s haematoxylin
(Fisher Scientific, Pittsburgh, PA), dehydrated and mounted.
TUNEL assay
The sections were deparaffinized and the TUNEL assay was
performed following the manufacturer’s instructions of a commer-
cially available kit (DeadEnd
TMFluorometric TUNEL System)from
Promega. Apoptotic cells exhibit a strong nuclear green fluorescence
that could be detected using a standard fluorescein filter. All cells
stained with DAPI exhibit a strong blue nuclear fluorescence. The
slides were observed under fluorescence microscopy with relative
apoptotic cells determined by counting TUNEL-positive cells in five
random fields (at 6100 magnification) for each sample.
Statistical analysis
The in vitro cytotoxicity experiments were performed in triplicate
for each time point and concentration. The significance of the in
vitro data was determined using the Student t test (2-tailed). P-
values less than 0.05 were considered statistically significant.
The gene mutations of the cell lines were obtained from online
database (http://www.sanger.ac.uk/genetics/CGP/CellLines/).
The correlations of the in vitro response to AZD6244 or
MK2206 (IC50) and gene mutations were assessed by using
Wilcoxon test and Logistic regression.
For the in vivo studies, tumor volumes were calculated as mean
6 standard deviation. Wilcoxon rank sum test and Kruskal-Wallis
test were used to compare treatment differences. Spearman
correlation coefficient was used to estimate the correlation
between two continuous variables. Treatment differences with
respect to survival were assessed via the log-rank test. All tests were
two-sided. P-values less than 0.05 were considered statistically
significant. Statistical software SAS 9.1.3 and S-PLUS 8.0 were
used for all the analyses.
Results
Effects of AZD6244 or MK2206 Single-drug Treatment on
Lung Cancer Cell Lines
Before evaluating the effects of the combination therapy, we
tested the antiproliferative effect of AZD6244 and MK2206 as
single-agent therapies on a panel of 47 human lung cancer cell lines
(Figure 1). The response to AZD6244 varied greatly, from highly
sensitive (IC50,0.2 mM) to highly resistant (IC50.150 mM), among
the cell lines. The dose response range of MK2206 was more
consistent, with the IC50 ranging from 0.4 mMt o2 5mM. We found
some cell lines were sensitive to AZD6244 but resistant to MK2206
(such as Calu-6, HCC1171, and H1993), while other cell lines were
resistant to AZD6244 but sensitive to MK2206 (such as H522,
H1395, and Calu-3). No correlation between the sensitivity to these
two compounds was observed. Comparing the dose-response results
and the online gene mutation database, no correlation was found
between EGFR, KRAS, BRAF or PI3K gene mutations and the
IC50 of AZD6244 or MK2206. We alsodid not observe correlations
between overall EGFR/KRAS/BRAF gene mutations and the
IC50 of AZD6244 or overall EGFR/PI3K gene mutations and the
IC50 of MK2206 (Table 1 and 2).
Effects of the AZD6244-MK2206 combination vary
among lung cancer cell lines
From the 47 cell lines, we chose 28 to test the antitumor effects
of AZD6244 and MK2206 combination therapy. The cell lines
were selected to represent a spectrum of sensitivity to one or both
drugs. The IC50 was .5uM for both AZD6244 and MK2206 for
21 of the 28 cell lines. For the other cell lines the IC50 was ,5uM
for AZD6244 or MK2206 or both. To determine if the antitumor
effects obtained with different AZD6244 and MK2206 combina-
tions were synergistic, we calculated the combination index (CI)
according to the Chou-Talalay method using Calculsyn software
(Biosoft, Cambridge, UK). (CI.1.1, antagonism; CI=0.9–1.1,
additive effect; CI=0.2–0.9, synergism; CI,0.2 strong synergism).
Since the Chou-Talalay model calls for cytotoxic agents to be used
at a fixed dose ratio, we chose to use AZD6244 and MK2206 at a
5:1 molar ratio. After treatment with various concentrations of
AZD6244 (0.024–100 mM), MK2206 (0.005–20 mM) and
AZD6244/MK2206 (0.024/0.005–100/20 mM), which are in
the range of concentrations achieved in the serum of patients
receiving oral AZD6244 and MK2206, the combination index
(CI) was measured on each cell line. In 67% of the cell lines,
including H2023, H2347, HCC827, and H23 shown in Figure 2,
the combination treatment produced a strong synergistic effect.
The combined treatment produced an additive or antagonistic
effect only in 11% of the cell lines (Table 3).
Synergistic effect of AZD6244-MK2006 combination
therapy is ratio-dependent
The fixed drug ratios were expanded for 7 cell lines (H1792,
H157, A549, H515, H1693, H1703 and H3122) that were
sensitive to the combination of AZD6244 and MK2206 to 8:1, 4:1,
2:1, 1:2, 1:4, and 1:8. We found that consistent synergism resulted
when the 8:1, 4:1, and 2:1 ratios were used (Figure 2, Table 4),
whereas decreasing the AZD6244:MK2206 ratio to 1:8 resulted in
a loss of synergy and produced an additive or antagonistic effect in
most cell lines (Table 4). We also found that each cell line had its
own optimal drug ratio. For example, H1703 showed the highest
level of synergism at an AZD6244:MK2206 ratio of 8:1; H1693
and A549 was highest at 4:1(Figure 3A, left); and H157 was
highest at 2:1 (Figure 3A, right).
MK2206 enhances the AZD6244-induced apoptosis
To determine if MK2206 had an effect on AZD6244-induced
apoptosis, we tested the expression of AKT, p-AKT, ERK, p-
ERK, and Bim and quantified apoptotic cells following treatment
with individual and combination agents. AZD6244 is known to
upregulate expression of Bim, a BH3-only protein, leading to a
mitochondrial pathway activation and apoptosis, mediated by
FOXO3a [6]. In addition, AKT can also phosphorylate
FOXO3a, and inhibition of AKT might enhance FOXO3a
activation by dephosphorylation. We noticed that treatment with
AZD6244 alone led to a relatively moderate overexpression of Bim
at 48 h. Although we did not detect an obvious change in Bim
expression following treatment with MK2206, when MK2206 was
combined with AZD6244, Bim expression increased to a level
higher than that induced by AZD6244 alone (Figure 3B). We also
found that the 2-drug combination resulted in more apoptotic cells
than either single-drug treatment alone. Once combined with
MK2206, AZD6244-induced apoptosis increased from 14.4% to
29.8% in the A549 cell line and from 6.0% to 27.0% in the H157
cell line (P,0.05, Figure 3C). These results indicate that MK2206
effectively enhanced AZD6244-induced activation of mitochon-
drial apoptosis.
Synergistic effect in vivo
Response to the AZD6244-MK2206 combination treatment in
vivo was evaluated in subcutaneous tumors generated by injection
Combine MEK and AKT Inhibitors
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Mice with established flank tumors of equal volumes were
treated with vehicle, a single AZD6244 administration, a single
MK2206 administration, or the AZD6244-MK2206 combina-
tion. In both the A549 and H157 subcutaneous xenograft mouse
models, mice receiving the combination of AZD6244 and
MK2206 showed a significantly reduced mean tumor volume
(1356120 and 1886107 mm
3) compared with mice receiving
AZD6244 alone (8486302 and 6696154 mm
3), MK2206 alone
(14976380 and 8586125 mm
3), or control treatment
(26666275 and 14376217 mm
3) by day 20 (P,0.01 for all
three comparisons; Figure 4A). This result indicates that
suppression of AKT with MK2206 increased the A549 and
H157 cells’ sensitivity to AZD6244 in vivo. In addition, we found
that animal survival times were longer in the groups that
received the 2-drug combination than in the groups that received
single-agent compounds or control treatment (Figure 4B). The
median survival time of animals treated with the AZD6244-
MK2206 combination increased significantly (P,0.01,
Figure 4B). In the A549 xenograft model, mice treated with
Figure 1. Response to AZD6244 or MK2206 alone in various lung cancer cell lines. The indicated cell lines were treated with different
concentrations of either AZD6244 or MK2206 for 96 h. Cell viability was determined using sulforhodamine B, and IC50 was calculated according to the
dose-response curve.
doi:10.1371/journal.pone.0014124.g001
Table 1. Correlations between the IC50 to AZD6244 and gene
mutations in lung cancer cell lines.
Gene mutation Wilcoxon Test Logistic Regression
P-value Significance P-value Significance
EGFR 0.6493 NS 0.4631 NS
KRAS 0.2740 NS 0.2871 NS
BRAF 0.8513 NS 0.3527 NS
PI3K 0.2973 NS 0.2874 NS




Table 2. Correlations between the IC50 to MK2206 and gene
mutations in lung cancer cell lines.
Gene mutation Wilcoxon Test Logistic Regression
P-value Significance P-value Significance
EGFR 0.2319 NS 0.4209 NS
KRAS 0.3206 NS 0.2710 NS
BRAF 0.1191 NS 0.2165 NS
PI3K 1.0000 NS 0.8898 NS
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those treated with AZD6244 alone, MK2206 alone, and control
vehicle had median survival times of 32 d, 23 d, and 17 d,
respectively (P,0.01 for all three comparisons). We had similar
results in the H157 xenograft model: the median survival times
for the combination therapy markedly increased to 45 d while
for AZD6244-alone, MK2206-alone, and control treatments
were 33.5 d, 33 d, and 26.5 d, respectively (p,0.01 for all three
comparisons). In addition, 20% of the H157 tumor-bearing mice
and 40% of A549 tumor-bearing mice that received the
combination treatment survived past 55 d and did not have
tumors at the final observation. Furthermore, no significant
differences in mouse body weight were found between the four
groups following the 20 d treatment, and there were no obvious
toxicities from the drug combination (data not shown). Together,
these results suggest that the combination of AZD6244 and
MK2206 has a synergistic therapeutic effect on human lung
cancer cell growth in a panel of NSCLC cell lines in vitro,a n di n
A549 and H157 cell lines in vivo.
Target modulation in A549 xenograft mouse model
In the pharmacodynamic study, four hours after the final dose on
day 3, the animals were euthanized and the tumors tissues were
excised and analyzed for p-ERK and p-AKT by immunohisto-
chemical staining. Inhibition of p-ERK expression was observed in
tumors of mice treated with AZD6244 alone or the AZD6244-
MK2206 combination. Inhibition of p-AKT was seen in tumors of
mice treated with MK2206 alone or the AZD6244-MK2206
combination (Figure 5A). The results indicated that p-ERK and p-
AKT were effectively inhibited with AZD6244 and MK2206 in vivo.
The combination of AZD6244 and MK2206 could also inhibit the
targets effectively. The TUNEL assay showed that MK2206
enhanced AZD6244-induced apoptosis significantly (P,0.05) from
2.6% to 11.2% in xenograft tumor tissue (Figure 5B).
Discussion
In this study we report that the combination therapy of MEK
inhibitor AZD6244 and AKT inhibitor MK2206 can induce
Figure 2. Dose-effect curves for the AZD6244-MK2206 combination for lung cancer cell lines. Lung cancer cell lines were treated with
various concentrations of AZD6244 (0.024–100 mM), MK2206 (0.005–20 mM) and AZD6244/MK2206 (0.024/0.005–100/20 mM) for 96 h. Dose-effect
curves of the combination and of each agent alone are presented for comparison. Representative cell lines that demonstrated the strong synergistic
effects of the combination therapy are shown.
doi:10.1371/journal.pone.0014124.g002
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Previously studies have observed that resistance to AZD6244 in
lung cancer cells is mediated by AKT activation [5,7]. The
feedback loop of RAS/RAF/MEK/ERK and PI3K/AKT
pathways prompted us to hypothesize that suppression of these
two pathways may overcome the resistance to AZD6244 and act
synergistically to inhibit the growth of lung cancer. In this study,
we showed that single-agent therapy with either AZD6244 or
MK2206 has a modest inhibitory effect on lung cancer cell lines.
Because certain gene mutations may be implicated in response to
these agents, we also checked the mutational status of BRAF,
KRAS, EGFR and PI3K in these cell lines. The BRAF V600E
mutation has been reported to be correlated with sensitivity to
MEK inhibitors [8,9] and has been used as a major criterion for
recruiting patients into a clinical trial of MEK inhibitors in
melanoma patients. KRAS, BRAF/KRAS, and LKB/KRAS
mutation(s) are correlated with sensitivity to MEK inhibitors in
ovarian cancer [10], colorectal cancer [11], and NSCLC [12],
respectively. However, we did not detect an obvious correlation
between mutational expression of EGFR, BRAF, PI3KI, or KRAS
and sensitivity to AZD6244 or MK2206 in the lung cancer lines
we tested. This may be due to the differing effects of the mutations
in specific histologic types of cancer or in cell line specific
pathways. For example, for breast and lung cancer, gene
expression associated with differential sensitivity to AZD6244
included many genes that were not in common for both histologies
[13]. Another possible explanation for the discrepancy of our
results and previous studies could be due to various frequencies of
gene mutations in different cancer types. For example, BRAF is
mutated in many cancers, including malignant melanoma (27–
70%), papillary thyroid cancer (36–53%), ovarian cancer (about
30%), and colorectal cancer (5–22%). However, BRAF mutations
are detected only in 1–2% of lung cancer patients. It would be
difficult to show statistically significant relationships with such low
frequency events.
Our investigation showed that the dual-agent AZD6244-
MK2206 combination therapy showed a synergistic effect on
tumor growth relative to either agent alone. As a single-agent
therapy, AZD6244 was ineffective against some lung cancer cell
lines (such as Calu-1, H460, and H661). However, when
combined with MK2206, these resistant cell lines were sensitive
to combination treatment. According to Chou-Talalay methods
[14], we used a fixed drug ratio to test for a synergistic effect. In
clinical trials, the combination therapy will be given to patients in
repeating 28-d cycles. The planned starting dose of MK2206 is
45 mg/kg every other day (the highest once every other day dose
of MK2206 will be 45 mg/kg) or 90 mg/kg once weekly and
increasing to as much as 250 mg/kg once weekly; the planned
starting dose of AZD6244 is 75 mg/kg twice daily (http://
clinicaltrials.gov/). We selected a drug ratio of 5:1
AZD6244:MK2206 which is in this range for our initial study in
vitro. Our results showed that AZD6244:MK2206 can induce
synergistic effects among 89% cell lines. To obtain a more
quantitative analysis, we expanded the drug ratios to identify the
most effective range and the optimal synergistic ratio. We found
that these two drugs showed consistently synergistic effects at 8:1,
4:1, and 2:1 ratios of AZD6244 to MK2206, whereas decreasing
this ratio to 1:8 resulted in a loss of synergy and the presence of
only additive effects or even antagonism in most cell lines. We then
selected two KRAS mutated cell lines, A549 and H157, to further
investigate the effect of AZD6244-MK2206 combination in vivo.
The tumor growth was inhibited significantly with combination
treatment compared to single agent treatment. The pharmacody-
namic effects in A549 xerografts showed that the expression level
Table 3. Combination index (CI) value of the combination
therapy of AZD6244 and MK2206 at the ratio of 5:1.






























Table 4. Combination index (CI) value of the combination
therapy of AZD6244 and MK2206 at the ratios of 8:1, 4:1, 2:1,
and 1:8.
Cell
Lines 8:1 4:1 2:1 1:8
50%CI 75%CI 50%CI 75%CI 50%CI 75%CI 50%CI 75%CI
H1792 0.1 0.26 0.22 0.1 0.39 0.83 1.01 1.03
H157 0.34 0.4 0.28 0.27 0.16 0.08 0.83 0.76
A549 0.26 0.39 0.1 0.12 0.21 0.24 0.99 0.79
H515 0.13 0.22 0.29 0.48 0.33 0.2 0.69 0.76
H1693 0.09 0.09 0.04 0.07 0.15 0.24 1.51 0.95
H1703 0.01 0.04 0.07 0.05 0.12 0.16 0.92 0.97
H3122 0.24 0.36 0.53 0.82 0.4 0.48 0.63 0.59
doi:10.1371/journal.pone.0014124.t004
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and MK2206 respectively. The combination of AZD6244 and
MK2206 inhibited both p-ERK and p-AKT effectively. The
TUNEL assay showed that combination treatment induced much
more tumor cell apoptosis than individual drugs. These results
strongly suggest that AZD6244 and MK2206 synergistically
induce apoptosis by dual inhibition of ERK and AKT
phosphorylation.
Previous studies have shown that whether anticancer drug
combinations interact synergistically or antagonistically can
Figure 3. Treatment with AZD6244 and MK2206 synergistically upregulated Bim expression and induced cell apoptosis. (A) A549
and H157 were treated with AZD6244, MK2206, or a combination of these two compounds at the indicated concentrations for 48 h. (B) Protein
specimens were harvested and AKT, p-AKT, ERK, p-ERK and Bim expression were detected with Western blot analysis. (C) Cells were trypsinized and
fixed, and the cell cycle was measured with flow cytometry. Numbers represent percentages of apoptotic sub-G1–phase cells. Data represent one of
three independent experiments with similar results. Columns, mean; bar, SD.*, P,0.05, compared with the single agent treatments.
doi:10.1371/journal.pone.0014124.g003
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control drug ratios because of uncoordinated mechanisms or
pharmacokinetics could therefore lead to drug resistance if the
tumor cells are exposed to antagonistic drug ratios. It is possible that
the precise ratios described in vitro may not be obtained in the tumor
of a patient due to the differential distribution and metabolism of
these two compounds. However, we found that the synergistic
effects occurred over a broad range of drug concentrations making
it likely that a therapeutic effect will be achieved.
In our mechanistic and in vivo studies, we used A549 and H157
cell lines because both of them harbor KRAS mutations.
Mutations in KRAS have been found in 20% to 30% of lung
cancers and are believed to play a key role in this malignancy [17].
The presence of a mutated KRAS gene is reportedly associated
with primary resistance to all targeted therapies [18]. The KRAS
mutation also serves as a strong predictor of non-responsiveness to
EGFR–targeted agents in lung and colon cancers [19]. Engelman
and colleagues [20] recently reported that the combination of
PI3K and MEK inhibitors led to marked synergistic tumor
regression in KRAS-mutant mouse lung tumors. They later
observed that an AKT inhibitor when combined with MEK
inhibitors, failed to induce apoptosis in human lung cancer cells
with mutant EGFR although these cells were sensitive to the
combination of PI3K and MEK inhibitors [21]. However, in our
study, we investigated that the combination therapy of MEK
inhibitors and AKT inhibitor has a strongly synergistic effect on
both EGFR mutant (such as HCC827) and EGFR wildtype cell
lines. There are several possible reasons to explain this difference.
Firstly, we used an allosteric inhibitor MK2206 in our study and
they used an AKT1/2 inhibitor. The AKT1/2 inhibitor may not
be as effective in inhibiting the three known isoenzymes of AKT
thus resulting in a negative feedback loop which interferes with the
efficacy of the combination therapy. Secondly, as the effect of the
AZD6244-MK2206 combination is drug ratio-dependent, it is
possible that the single drug ratio used in Engleman’s study might
not be the optimal ratio to induce synergy. Nevertheless, the
efficacy of the combined suppression of ERK and AKT in KRAS-
mutated cell lines confirm the strategy of dual downstream target
inhibition converging on a common effector pathway, as
previously reported by She et al [22], Legrier et al [23], Engelman
et al [20] and Mordant et al [24]. This combination strategy
represents a promising therapeutic strategy for tumors resistant to
targeted therapies used as single agents.
In conclusion, our finding that the combination of AZD6244
and MK2206 results in a synergistic effect on inhibiting NSCLC
cell growth and increasing survival times for mice bearing NSCLC
xenografts may lead to an effective drug combination treatment
strategy for lung cancer patients.
Figure 4. Effect of AZD6244-MK2206 combination on tumor growth and survival in mice. Flank tumors were established in nude mice
and treated with vehicle, AZD6244, MK2206, or combination AZD6244-MK2206 therapy orally twice a day at indicated doses. (A) Tumor volumes.
Overall differences between treatments were statistically significant (P,0.001; Kruskal-Wallis Test). We observed statistically significant time-by-
treatment effects when comparing Control vs A (P,0.05); Control vs M (P,0.05); Control vs A+M( P,0.05); A vs M (P=0.05); A vs A+M( P=0.05) and
Mv sA +M( P,0.05) for A549; results were similar for H157 except that A vs. M was not statistically significant. (B) Survival times. Overall differences
between treatments were statistically significant (P,0.001; Log-RankTest).
doi:10.1371/journal.pone.0014124.g004
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